Max dose: 6.8mg/day. Allow tab to dissolve on the tongue; swallow without water. Patients receiving 2mg dose of another oral tab form of glycopyrrolate may switch to 1.7mg dose of Dartisla ODT.

Edenbridge Pharmaceuticals, LLC today announced that it has received approval from the U.S. Food and Drug Administration on its 505 New Drug Application for DARTISLA ODT orally disintegrating tablets.

Dartisla ODT is supplied as 1.7mg glycopyrrolate orally disintegrating tablets in 30-count cartons, and is expected to be available in early 2022.